Swiss drugmaker Novartis is accused of offering rebates and discounts to compel 20 pharmacies to ask physicians to switch kidney transplant patients to Novartis' Myfortic immunosuppressant. The alleged scheme led Medicare and Medicaid to pay millions of dollars extra, the U.S. government said in a civil suit.

Related Summaries